Home management of INR in the public health system: feasibility of self-management of oral anticoagulation and long-term performance of individual POC devices in determining INR.

Abstract:

:The home prothrombin time/international normalized ratio (PT/INR) self-management could be convenient for patients, enhancing treatment compliance and improving the quality of the oral anticoagulation. However, patient self-management (PSM) of oral anticoagulation may not be feasible for up to half of the patients due to cognitive or educational issues. In the present study, we aimed to evaluate the feasibility of a PSM program in a public health medical center that provides care for low-income patients. We also aimed to determine the accuracy of individual point-of-care devices (CoaguChek XS(®)) during long-term of home manipulation. Patients' time-in-therapeutic range (TTR) and perception of quality of life, were evaluated at scheduled study-visits to the center. Additionally, the accuracy of individual CoaguChek XS(®) was evaluated in comparison to the standard automated coagulometer at scheduled study-visits to the center. Twenty-five patients were included in the PSM program. The median TTR of patients was 75 % before inclusion, 72 % at 3 months, 75 % at 6 months and 100 % at 12 months after the beginning of self-management (P = 0.14).The median DASS scores were 64, 63, 61.5 and 71.5 before inclusion and at 3, 6 and 12 months, respectively (P = 0.09). One hundred paired INR values were obtained. Correlation between INR values delivered by individual CoaguChek XS(®) and the automated coagulometer was 94 % and the mean result bias was 0.07 INR units. The coefficient of correlation and the mean bias between methods was stable during 24 months of follow-up. The present study suggests that PSM is feasible for patients treated in the public health system and that the results delivered by CoaguChek XS(®) have long-term reliability.

journal_name

J Thromb Thrombolysis

authors

da Silva Saraiva S,Orsi FA,Santos MP,Machado T,Montalvão S,Costa-Lima C,de Paula EV,Colella MP,Annichino-Bizzacchi J

doi

10.1007/s11239-016-1335-6

subject

Has Abstract

pub_date

2016-07-01 00:00:00

pages

146-53

issue

1

eissn

0929-5305

issn

1573-742X

pii

10.1007/s11239-016-1335-6

journal_volume

42

pub_type

杂志文章
  • Treatment of patients with a history of heparin-induced thrombocytopenia and anti-lepirudin antibodies with argatroban.

    abstract::Patients with heparin-induced thrombocytopenia (HIT) type II require anticoagulation with non-heparin immediate acting anticoagulants. Danaparoid may cross react with HIT-antibodies and lepirudin may generate anti-lepirudin antibodies influencing anticoagulation. We hypothesised, that the synthetic small molecular thr...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-005-0942-4

    authors: Harenberg J,Jörg I,Fenyvesi T,Piazolo L

    更新日期:2005-02-01 00:00:00

  • Dabigatran versus warfarin major bleeding in practice: an observational comparison of patient characteristics, management and outcomes in atrial fibrillation patients.

    abstract::Data comparing the patient characteristics, management and outcomes for dabigatran versus warfarin major bleeding in the practice setting are limited. We performed a retrospective single health system study of atrial fibrillation patients with dabigatran or warfarin major bleeding from October 2010 through September 2...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-015-1213-7

    authors: Smythe MA,Forman MJ,Bertran EA,Hoffman JL,Priziola JL,Koerber JM

    更新日期:2015-10-01 00:00:00

  • Low levels of activated factor VII in systemic sclerosis.

    abstract:INTRODUCTION:Recent investigations show that activated factor VII, the primary enzyme in the extrinsic pathway of blood coagulation, exerts additional extra-coagulant functions, such as apoptosis and angiogenesis. On the basis of these recent acquisitions, the present study was aimed to evaluate activated factor VII in...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-006-8969-8

    authors: Volpe A,Salvagno GL,Lippi G,Caramaschi P,Montagnana M,Canestrini S,Carletto A,Bambara LM,Biasi D,Guidi GC

    更新日期:2006-10-01 00:00:00

  • Aspirin administered to women at 100 mg every other day produces less platelet inhibition than aspirin administered at 81 mg per day: implications for interpreting the women's health study.

    abstract:OBJECTIVE:We aimed to determine the relative level of platelet inhibition achieved with low-dose aspirin (81 mg daily) compared with a very low-dose (100 mg every other day). BACKGROUND:The Womens Health Study (WHS) found that a dose of 100 mg every other day of aspirin provided protection against stroke as primary pr...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-008-0262-6

    authors: Swaim L,Hillman RS

    更新日期:2009-07-01 00:00:00

  • Development of a new catheter prototype for laser thrombolysis under guidance of optical coherence tomography (OCT): validation of feasibility and efficacy in a preclinical model.

    abstract::In this feasibility study, a novel catheter prototype for laser thrombolysis under the guidance of optical coherence tomography (OCT) was designed and evaluated in a preclinical model. Human arteries and veins were integrated into a physiological flow model and occluded with thrombi made from the Chandler Loop. There ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-016-1470-0

    authors: Berndt R,Rusch R,Hummitzsch L,Lutz M,Heß K,Huenges K,Panholzer B,Otte C,Haneya A,Lutter G,Schlaefer A,Cremer J,Groß J

    更新日期:2017-04-01 00:00:00

  • Treatment of Deep Vein Thrombosis with Low Molecular Weight Heparin at Patient's Home.

    abstract::We have applied the low molecular weight heparin dalteparin as once-daily subcutaneous injections to the treatment of deep vein thrombosis (DVT) on an outpatient basis since 1994. Until today, 377 consecutive patients with DVT below the inguinal ligament have been treated at home with dalteparin. The patients administ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/A:1008866025015

    authors: Stockelberg D,Hansson E,Jonson T

    更新日期:1998-09-01 00:00:00

  • Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update.

    abstract::Cancer is associated with an increased risk of venous thromboembolism of four to sixfold. Cancer-related interventions such as chemotherapy, hormonal therapy and indwelling central venous catheters also increase the risk of venous thromboembolism. Low molecular weight heparin for at least 3-6 months is the current sta...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-018-1783-2

    authors: Franco-Moreno A,Cabezón-Gutiérrez L,Palka-Kotlowsa M,Villamayor-Delgado M,García-Navarro M

    更新日期:2019-04-01 00:00:00

  • Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy.

    abstract::Direct oral anticoagulants are associated with rates of major bleeding which are not negligible, albeit lower than those associated with vitamin K antagonists. No specific reversal agent for factor Xa (FXa) direct inhibitors is currently available for clinical use. A modified activated human FXa decoy protein, andexan...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-018-1617-2

    authors: Sartori M,Cosmi B

    更新日期:2018-04-01 00:00:00

  • Thrombolysis in Acute Myocardial Infarction Complicated by Cardiogenic Shock.

    abstract::The adverse impact of the development of cardiogenic shock in the setting of acute myocardial infarction was first described by Killip and Kimball in 1967. While the in-hospital mortality rate in patients with myocardial infarction and no evidence of heart failure was only 6%, the mortality rate in those patients who ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/BF01063156

    authors: Levine GN,Hochman JS

    更新日期:1995-01-01 00:00:00

  • Outpatient Therapy of Deep Vein Thrombosis.

    abstract::The initial treatment of acute venous thrombosis using low-molecular-weight heparin (LMWH) in the outpatient setting has been shown to be feasible, effective, and safe for selected patients when compared with in-hospital treatment using continuous intravenous heparin. There will always be a significant population of p...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1023/a:1013232803747

    authors: Pineo GF,Hull RD

    更新日期:1998-01-01 00:00:00

  • Awareness and management of pulmonary embolism among physicians in China: a nationwide cross-sectional study.

    abstract::Pulmonary embolism (PE) is a leading cause of cardiovascular mortality. We intended to evaluate the awareness and management status of PE among Chinese physicians and provide the basis for establishing Chinese clinical guidelines on PE. We designed a nationwide survey to collect data on physicians' awareness of diagno...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-018-1788-x

    authors: Zhang M,Zhang YX,Zhang Z,Wang J,Shao X,Xie WM,Wan J,Zhai ZG,Wang C

    更新日期:2019-04-01 00:00:00

  • Pharmacokinetics of rivaroxaban after bariatric surgery: a case report.

    abstract::Rivaroxaban is a direct factor Xa inhibitor, which is rapidly absorbed in the upper gastrointestinal (GI) tract. In large trials, it has been shown to be effective and safe in VTE treatment. However, in these trials patients with morbid obesity were not reported and it is unknown if the standard dosage of 20 mg rivaro...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-013-0891-2

    authors: Mahlmann A,Gehrisch S,Beyer-Westendorf J

    更新日期:2013-11-01 00:00:00

  • A dose-finding clinical trial of staphylokinase SY162 in patients with long-term venous access catheter thrombotic occlusion.

    abstract:BACKGROUND:We investigated the safety and efficacy of several dosing regimens of catheter-directed staphylokinase (SY162) bolus administration for the treatment of long-term venous access catheter occlusion. METHODS:This open-label, ascending dose study enrolled 24 subjects. Three doses of SY162 were evaluated in thre...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-006-0006-4

    authors: Verhamme P,Goossens G,Maleux G,Collen D,Stas M

    更新日期:2007-08-01 00:00:00

  • Oral anticoagulation control: the European perspective.

    abstract::We describe the results of a novel complete care package using point-of-care INR testing and computerized decision support for the management of oral anticoagulation by nurse-led primary care clinics in the United Kingdom. We found such therapy to be as safe and effective as traditional hospital-based care for oral an...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-006-5584-7

    authors: Fitzmaurice DA

    更新日期:2006-02-01 00:00:00

  • Vincristine induces procoagulant activity of the human lymphoblastic leukemia cell line Jurkat through the release of extracellular vesicles.

    abstract::Thromboembolic events are frequent and serious complications of acute lymphoblastic leukaemia treatment. The importance of chemotherapy in the pathogenesis of this increased risk is enhanced by the fact that thrombosis rarely occurs at diagnosis. Our study aims at investigating the effect of chemotherapy on pro-coagul...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-019-01894-x

    authors: Pluchart C,Poitevin G,Colinart-Thomas M,Guimard G,Audonnet S,Terryn C,Nguyen P

    更新日期:2019-08-01 00:00:00

  • Thrombosis, anticoagulation and outcomes in malignant superior vena cava syndrome.

    abstract::Anticoagulation is often used in superior vena cava syndrome (SVCS) associated with cancer (i.e malignant SVCS), even without thrombosis, but its effect on outcomes has not been reported. We aimed to determine factors and outcomes associated with thrombosis and anticoagulation in malignant SVCS. Patients with malignan...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-018-1747-6

    authors: Ratzon R,Tamir S,Friehmann T,Livneh N,Dudnik E,Rozental A,Hamburger-Avnery O,Pereg D,Derazne E,Brenner B,Raanani P,Ten Cate H,Spectre G,Leader A

    更新日期:2019-01-01 00:00:00

  • Characteristic and prognosis of acute large vessel occlusion in anterior and posterior circulation after endovascular treatment: the ANGEL registry real world experience.

    abstract::There were limited studies comparing the anterior (AC) and posterior (PC) circulation acute ischemic strokes (AIS). Our study aimed to evaluate distinct features of AC and PC strokes regarding clinical, vascular risk, pathogenesis and outcome factors after endovascular procedures. This multicenter prospective study re...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02054-2

    authors: Huo X,Raynald,Gao F,Ma N,Mo D,Sun X,Song L,Jia B,Pan Y,Wang Y,Liu L,Zhao X,Wang Y,Miao Z,ANGEL investigators.

    更新日期:2020-05-01 00:00:00

  • Acute ischemic stroke patients with diabetes should not be excluded from intravenous thrombolysis.

    abstract::The benefit of intravenous thrombolysis (IVT) has been questioned for patients with diabetes mellitus (DM) in cases of acute ischemic stroke (IS). Our objective was to analyze the differences in outcome according to prior diagnosis of DM and the use or not of IVT. Observational study with inclusion of consecutive IS p...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-014-1110-5

    authors: Fuentes B,Cruz-Herranz A,Martínez-Sánchez P,Rodríguez-Sanz A,Ruiz Ares G,Prefasi D,Sanz-Cuesta BE,Lara-Lara M,Díez-Tejedor E

    更新日期:2014-11-01 00:00:00

  • The lack of endothelization after drug-eluting stent implantation as a cause of fatal late stent thrombosis.

    abstract::The authors present a fatal case of late thrombosis of paclitaxel-eluting stent implanted in the left main stem occurring 6 months after the procedure and 3 weeks after the cessation of clopidogrel. An autopsy has shown the lack of endothelization of deployed stent. ...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-007-0080-2

    authors: Jakabcin J,Bystron M,Spacek R,Veselka J,Kvasnak M,Kala P,Malý J,Cervinka P

    更新日期:2008-10-01 00:00:00

  • Circulating lipid levels and risk of coronary artery disease in a large group of patients undergoing coronary angiography.

    abstract::A main underlying pathology of coronary artery disease is the deposition of cholesterol in the arteries supplying blood to the heart that leads to stenosis and myocardial infarction. We tested if dyslipidemia is a risk factor for coronary artery disease in the Lebanese population, and studied the role of the total cho...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1007/s11239-014-1069-2

    authors: Platt DE,Ghassibe-Sabbagh M,Youhanna S,Hager J,Cazier JB,Kamatani Y,Salloum AK,Haber M,Romanos J,Doueihy B,Mouzaya F,Kibbani S,Sbeite H,Deeb ME,Chammas E,El Bayeh H,Khazen G,Gauguier D,Zalloua PA,Abchee AB,FGENTCA

    更新日期:2015-01-01 00:00:00

  • Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype-dependent influence of dietary vitamin K intake.

    abstract::Warfarin is the most widely prescribed oral anticoagulant, but large interindividual variations exist in the dose required to achieve comparable therapeutic effects. Several clinical and genetic variables have been identified that influence warfarin dosing. However, interactions between genotype and nutrition remain u...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 临床试验,杂志文章

    doi:10.1007/s11239-013-0978-9

    authors: Saito R,Takeda K,Yamamoto K,Nakagawa A,Aoki H,Fujibayashi K,Wakasa M,Motoyama A,Iwadare M,Ishida R,Fujioka N,Tsuchiya T,Akao H,Kawai Y,Kitayama M,Kajinami K

    更新日期:2014-07-01 00:00:00

  • Circulating p53 and cytochrome c levels in acute myocardial infarction patients.

    abstract:BACKGROUND:Apoptosis causes myocardiocyte loss during and after myocardial infarction. Therapeutic approaches designed to arrest apoptosis would be a significant new development in the recovery of acute myocardial infarction (AMI). In order to examine apoptotic markers in the circulation, serum levels of p53 and cytoch...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-009-0328-0

    authors: Dincer Y,Himmetoglu S,Bozcali E,Vural VA,Akcay T

    更新日期:2010-01-01 00:00:00

  • Genetic determinants of platelet response to clopidogrel.

    abstract::Antiplatelet agents are the mainstay treatment in the prevention and management of atherothrombotic complications. However, a substantial interpatient variability in response to clopidogrel has been reported. Furthermore, patients with coronary artery disease and lesser platelet inhibition in response to clopidogrel a...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,评审

    doi:10.1007/s11239-011-0611-8

    authors: Kubica A,Kozinski M,Grzesk G,Fabiszak T,Navarese EP,Goch A

    更新日期:2011-11-01 00:00:00

  • Renal Vein Thrombosis and Selective Arterial or Venous Thrombolytic Therapy.

    abstract::Background: Renal vein thrombosis (RVT) complicating the nephrotic syndrome is associated with a poor prognosis. Methods/Results: RVT was diagnosed in 12 of 60 patients with a diagnosis of nephrotic syndrome suggested by computed tomography (CT) and subsequently confirmed by selective renal angiography. Fifty patients...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/BF00226414

    authors: Wu ZL,Zhou KR,Liao Lt

    更新日期:1996-01-01 00:00:00

  • Characteristics and risk factors of deep vein thrombosis in hemiplegic, healthy and bilateral limbs of hemiplegic patients: a 10-year retrospective study.

    abstract::Deep vein thrombosis (DVT) in hemiplegic patients mainly affects hemiplegic limbs, DVT can also occur only in healthy limbs, and some hemiplegic patients have DVT in both limbs. Characteristics and risk factors of DVT in hemiplegic, healthy, and bilateral limbs are unknown. To describe the proportion, risk factors, ex...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02254-w

    authors: Liang F,Chao M,Li JB,Ye XM

    更新日期:2020-08-27 00:00:00

  • Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case-control study.

    abstract::The relation of device related thrombosis (DRT) and major bleeding after left atrial appendage closure (LAAC) to laboratory thrombosis and hemostasis markers has not been studied. We performed a prospective case control study to identify clinical characteristics and laboratory markers in patients who developed DRT and...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02205-5

    authors: Sherwood M,Bliden KP,Ilkhanoff L,Venkataraman G,Strickberger A,Yazdani S,McSwain R,Rashid H,Navarese EP,Plummer T,Batchelor W,Chaudhary R,Tantry US,Gurbel PA

    更新日期:2020-10-01 00:00:00

  • Impact of early abciximab administration on myocardial reperfusion in patients with ST-segment elevation myocardial infarction pretreated with 600 mg of clopidogrel before percutaneous coronary intervention.

    abstract::Early rapid platelet inhibition with abciximab before primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI) is suggested as beneficial. In previous studies on early abciximab administration clopidogrel was administered in cathlab in low loading dose. We investigated t...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1007/s11239-010-0461-9

    authors: Dudek D,Rakowski T,Bartus S,Giszterowicz D,Dobrowolski W,Zmudka K,Zalewski J,Ochala A,Wieja P,Janus B,Dziewierz A,Legutko J,Bryniarski L,Dubiel JS

    更新日期:2010-10-01 00:00:00

  • Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?

    abstract::Patients with Coronavirus-associated disease-2019 (COVID-19) display alterations of the hemostatic system and the presence of a prothrombotic status frequently leading to vascular complications. However, the impact of COVID-19 on platelet activity, aggregation and agglutination still needs to be clarified. We measured...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-020-02339-6

    authors: Ruberto F,Chistolini A,Curreli M,Frati G,Marullo AGM,Biondi-Zoccai G,Mancone M,Sciarretta S,Miraldi F,Alessandri F,Ceccarelli G,Barone F,Santoro C,Alvaro D,Pugliese F,Pulcinelli FM,Policlinico Umberto I COVID-19 Group.

    更新日期:2021-01-02 00:00:00

  • Differing coagulation profiles of patients with monoclonal gammopathy of undetermined significance and multiple myeloma.

    abstract::The link between myeloma and thrombosis is well established. Monoclonal gammopathy of undetermined significance (MGUS) has also been associated with an increased risk of thrombosis. It was recently demonstrated that patients with myeloma display changes in thromboelastometry that may indicate a prothrombotic state. Th...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-014-1140-z

    authors: Crowley MP,Quinn S,Coleman E,Eustace JA,Gilligan OM,O'Shea SI

    更新日期:2015-02-01 00:00:00

  • Does clopidogrel increase the degree of platelet inhibition when a platelet glycoprotein IIb/IIIa inhibitor has been given? Insights from an optical platelet aggregometry study.

    abstract:INTRODUCTION:While the CURE trial demonstrated the benefits of clopidogrel in acute coronary syndromes, patients receiving glycoprotein IIb/IIIa antagonists were excluded. Given the frequent coadministration of these two medications, we sought to examine their interaction and their combined effect on platelet inhibitio...

    journal_title:Journal of thrombosis and thrombolysis

    pub_type: 杂志文章

    doi:10.1007/s11239-004-0170-3

    authors: Talreja D,Lubbe D,Orford JL,Lennon R,DiBattiste PM,Berger PB

    更新日期:2004-08-01 00:00:00